---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-228185"
form_type: "8-K"
ticker: "KURA"
cik: "0001422143"
company_name: "Kura Oncology, Inc."
filed_at: "2021-07-29T23:59:59+00:00"
generated_at: "2026-06-30T00:55:39.513608+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Kura Oncology appoints Helen Collins, M.D. as Class II director

## Summary
- Appointed effective July 28, 2021; term expires at 2022 annual meeting.
- Previously EVP and CMO at Five Prime Therapeutics, led bemarituzumab development until Amgen acquisition in April 2021.
- Received options for 46,000 shares (3-year vest) and 19,166 shares (1-year vest); annual cash retainer $40,000.
- Annual automatic option grants of 23,000 shares on each annual meeting date, vesting over one year.

## SEC filing metadata
- accession: 0001193125-21-228185
- form_type: 8-K
- ticker: KURA
- cik: 0001422143
- company_name: Kura Oncology, Inc.
- filed_at: 2021-07-29T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422143/000119312521228185/0001193125-21-228185-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422143/000119312521228185/d200489d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-228185
- JSON: https://secwatch.observer/filing/0001193125-21-228185.json
- Plain text: https://secwatch.observer/filing/0001193125-21-228185.txt

## Key facts
- Executive change
  Helen Collins, M.D. was appointed as Class II director at Kura Oncology, Inc..
  - Action: appointed
  - Role: Class II director
  source text: appointed Helen Collins, M.D. as a Class II director of the Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/1422143/000119312521228185/0001193125-21-228185-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.